Impact of Omnipod 5 automated insulin delivery on continuous glucose monitoring metrics and predictors of improvement in time in range
Omnipod 5 is associated with significant and sustained improvements in CGM metrics and HbA1c, particularly in individuals with higher baseline HbA1c. The results suggest the potential benefits of prioritizing AID for individuals at greatest risk of complications.
Authors
- Fraser W. Gibb (ORCID: https://orcid.org/0000-0002-5576-6463)
- Shareen Forbes (ORCID: https://orcid.org/0000-0002-9127-0641)
- Roland H. Stimson (ORCID: https://orcid.org/0000-0002-9002-6188)
- S. Mackenzie (ORCID: https://orcid.org/0000-0001-7607-8099)
- Mark W. J. Strachan (ORCID: https://orcid.org/0000-0003-2628-1202)
- Anna R. Dover
- Marcus J. Lyall (ORCID: https://orcid.org/0000-0002-2952-2676)
- Emily M. McMurray
- Rohana J. Wright
- Gayle McRobert
Institutions
- NHS Lothian (GB)
- The Queen's Medical Research Institute (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- Diabetic Medicine
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1111/dme.70137
- Citations
- 1
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Insulet Corporation
- Dexcom
- Novo Nordisk